Our Programs
Pipeline
Pipeline

Overcoming the hurdles
presented by inherited retinal disease

ATSENA THERAPEUTICS’ programs include cutting-edge gene therapies for Leber congenital amaurosis 1 (LCA1), X-linked retinoschisis (XLRS) and MYO7A-associated Usher syndrome (USH1B). Our pipeline of proprietary assets is powered by adeno-associated virus (AAV) technologies tailored to overcome the hurdles presented by inherited retinal disease.

Program Indication Preclinical Ind-Enabling Phase I/II Pivotal
ATSN-101 LCA1
ATSN-201 XLRS
ATSN-301 USH1B
Undisclosed
Undisclosed
Undisclosed
accessibility optionsAccessibility
Text Size
A
A